Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 06: 524 - 528

DOI: https://doi.org/10.16139/j.1007-9610.2023.06.07

Original article

Study on invasive histopathological features of papillary thyroid carcinoma with tall cell variant

Expand
  • Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2023-09-18

  Online published: 2024-03-04

Fold

Abstract

Objective To study the invasive histopathological features of papillary thyroid carcinoma(PTC) with tall cell variant(TCV). Methods A retrospective analysis of 19 170 cases of PTC in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from January 2018 to May 2023 was performed to analyze and the clinicopathological features between TCV-PTC group and classic PTC (cPTC) group. Results Pathological results showed 1 380 cases in TCV-PTC group and 15 578 cases in cPTC group. TCV-PTC had higher proportion and (or) mean value in patients' age, extraglandular invasion, nerve invasion, vascular invasion, maximum diameter of cancer focus, multifocality，lymph node metastasis and BRAF mutation, but the proportion of patients with coexistent Hashimoto's thyroiditis was lower than cPTC， and all results had significant difference (P<0.05). Conclusions Compared with the cPTC, TCV-PTC has stronger local invasive characteristics and lymph node metastasis rate, which provides the basis for the subsequent clinical treatment.

Key words： Papillary thyroid carcinoma; Tall cell variant; Histopathological feature; Tumor invasion and metastasis

Cite this article

LIAO Zhenyu, ZHAO Qiwu, KUANG Jie, LIU Zhuoran, SUN Hanxing, WANG Yue, QIU Weihua, CHEN Xi, YAN Jiqi . Study on invasive histopathological features of papillary thyroid carcinoma with tall cell variant[J]. Journal of Surgery Concepts & Practice, 2023 , 28(06) : 524 -528 . DOI: 10.16139/j.1007-9610.2023.06.07

References

[1] KITAHARA C M, SOSA J A. Understanding the ever-changing incidence of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(11):617-618.
[2] CARLING T, UDELSMAN R. Thyroid cancer[J]. Annu Rev Med, 2014, 65:125-137.
[3] MICHELS J J, JACQUES M, HENRY-AMAR M, et al. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma[J]. Hum Pathol, 2007, 38(2):212-219.
[4] CHOI Y J, SHIN J H, KIM J H, et al. Tall cell variant of papillary thyroid carcinoma: sonographic and clinical findings[J]. J Ultrasound Med, 2011, 30(6):853-858.
[5] AXELSSON T A, HRAFNKELSSON J, OLAFSDOTTIR E J, et al. Tall cell variant of papillary thyroid carcinoma: a population-based study in Iceland[J]. Thyroid, 2015, 25(2):216-220.
[6] MORRIS L G, SHAHA A R, TUTTLE R M, et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival[J]. Thyroid, 2010, 20(2):153-158.
[7] BONGERS P J, KLUIJFHOUT W P, VERZIJL R, et al. Papillary thyroid cancers with focal tall cell change are as aggressive as tall cell variants and should not be considered as low-risk disease[J]. Ann Surg Oncol, 2019, 26(8):2533-2539.
[8] HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133.
[9] LIMBERG J, ULLMANN T M, STEFANOVA D, et al. Does aggressive variant histology without invasive features predict overall survival in papillary thyroid cancer? a national cancer database analysis[J]. Ann Surg, 2021, 274(3):e276-e281.
[10] HERNANDEZ-PRERA J C, MACHADO R A, ASA S L, et al. Pathologic reporting of tall-cell variant of papillary thyroid cancer: have we reached a consensus?[J]. Thyroid, 2017, 27(12):1498-1504.
[11] BAI Y, KAKUDO K, JUNG C K. Updates in the pathologic classification of thyroid neoplasms: a review of the world health organization classification[J]. Endocrinol Metab (Seoul), 2020, 35(4):696-715.
[12] LIVOLSI V A. Papillary carcinoma tall cell variant (TCV): a review[J]. Endocr Pathol, 2010, 21(1):12-15.
[13] WU S S, JOSHI N, SHARRETT J, et al. Risk factors associated with recurrence and death in patients with tall cell papillary thyroid cancer: a single-institution cohort study with predictive nomogram[J]. JAMA Otolaryngol Head Neck Surg, 2023, 149(1):79-86.
[14] ZHANG Y, MEI F, HE X, et al. Reconceptualize tall-cell variant papillary thyroid microcarcinoma: from a "sonographic histology" perspective[J]. Front Endocrinol (Lausanne), 2022, 13:1001477.
[15] LIU Z, ZENG W, CHEN T, et al. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis[J]. Oncotarget, 2017, 8(4):6222-6232.
[16] VUONG H G, LONG N P, ANH N H, et al. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis[J]. Endocr Connect, 2018, 7(12):R286-R293.
[17] HAWK W A, HAZARD J B. The many appearances of papillary carcinoma of the thyroid[J]. Cleve Clin Q, 1976, 43(4):207-215.
[18] VAN DEN BREKEL M W, HEKKENBERG R J, ASA S L, et al. Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma[J]. Laryngoscope, 1997, 107(2):254-259.
[19] GANLY I, IBRAHIMPASIC T, RIVERA M, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features[J]. Thyroid, 2014, 24(4):662-670.
[20] BALOCH Z W, ASA S L, BARLETTA J A, et al. Overview of the 2022 WHO classification of thyroid neoplasms[J]. Endocr Pathol, 2022, 33(1):27-63.
[21] LUNDGREN C I, HALL P, DICKMAN P W, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study[J]. Cancer, 2006, 106(3):524-531.
[22] XU J, DING K, MU L, et al. Hashimoto's thyroiditis: a "double-edged sword" in thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2022, 13:801925.
[23] XU S, HUANG H, QIAN J, et al. Prevalence of Hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes[J]. JAMA Netw Open, 2021, 4(7):e2118526.
[24] SULAIEVA O, CHERNENKO O, SELESNOV O, et al. Mechanisms of the impact of Hashimoto thyroiditis on papillary thyroid carcinoma progression: relationship with the tumor immune microenvironment[J]. Endocrinol Metab (Seoul), 2020, 35(2):443-455.
Options
Outlines

/

〈 〉